个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Huang Yihua[a] * ; Xu Chunwei[b] * ; Sun Yuanliang[c] * ; Wang Wenxian[d] ; Li Xingya[e] ; Liao Jun[a] ; Pang Lanlan[a] ; Zeng Liang[f] ; Li Juan[g] ; Wang Xihua[h] ; Zhang Qi[i] ; Xie Zhanhong[j] ; Xiao Lin[k] ; Gan Jiadi[a] ; Fang Wenfeng[a] ;
机构： [a]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China [b]Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 Zhongshan Road, Nanjing 210002, People’s Republic of China [c]Department of Respiratory and Critical Care, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510060, People’s Republic of China [d]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital, No. 1 Banshan East Street, Gongshu District, Hangzhou 310022, People’s Republic of China [e]Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, People’s Republic of China [f]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, People’s Republic of China [g]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 4th Section, People’s South Road, Chengdu 610041, People’s Republic of China [h]Department of Respiratory Medicine, Zhongda Hospital Southeast University, Nanjing 210009, People’s Republic of China [i]The First Affiliated Hospital of Jiaxing University, Jiaxing 314000, People’s Republic of China [j]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, People’s Republic of China k Radiotherapy Center, Jiangmen Central Hospital, Jiangmen 529020, People’s Republic of China
出处：
DOI： 10.1016/j.lungcan.2022.08.012
ISSN：

关键词： Non-small-cell lung cancer EGFR E709-T710delinsX Tyrosine kinase inhibitors Chemotherapy

摘要：
Currently, whether patients with rare epidermal growth factor receptor (EGFR) mutations could benefit from EGFR tyrosine kinase inhibitors (TKIs) demands further studies. Limited clinical data are available regarding the molecular characteristics and clinical response in non-small-cell lung cancer (NSCLC) patients harboring EGFR E709-T710delinsX mutations, a rare mutation type in exon 18 of EGFR. In this study, we aimed to explore the molecular distribution and clinical outcome of EGFR E709-T710delinsX mutated Chinese patients.Next-generation sequencing (NGS) tests were performed in 15,078 NSCLC patients. A multicenter retrospective cohort involving 17 advanced lung cancer patients with EGFR E709-T710delinsX was collected to evaluate clinical responses to diverse therapies. In silico protein structure modeling was conducted to predict drug response.5905 EGFR mutant patients (39.2%, 5905/15078) were identified, with 26 cases (0.44%, 26/5905) harbored EGFR E709-T710delinsD. Afatinib showed a better overall objective response rate (ORR) compared with the first-generation (1G) EGFR TKIs and chemotherapy with significant difference. Superior progression free survival (PFS) was also observed in patients treated with afatinib (afatinib 10.85 m vs 1G EGFR TKIs 4.0 m vs chemotherapy 2.8 m, p = 0.0007). In silico protein structure modeling predicts better binding of afatinib with EGFR E709-T710delinsD compared with other EGFR TKIs.This is the largest studies for EGFR E709-T710delinsX, with 26 cases with EGFR E709-T710delinsX being identified (0.44% in EGFR mutant NSCLC, 0.17% in NSCLC patients). This study also firstly revealed that afatinib might exert superior antitumor activity to the 1G EGFR TKIs and chemotherapy in EGFR E709-T710delinsX mutant patients.Copyright © 2022 Elsevier B.V. All rights reserved.

基金：
Chinese National Natural Science Foundation Project [grant number 82173101].
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 呼吸系统 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区：
出版当年[2022]版：
Q2 ONCOLOGY Q2 RESPIRATORY SYSTEM
最新[2023]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [a]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Huang Yihua,Xu Chunwei,Sun Yuanliang,et al.Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients[J].LUNG CANCER.2022,172:117-123.doi:10.1016/j.lungcan.2022.08.012.
APA：
Huang Yihua,Xu Chunwei,Sun Yuanliang,Wang Wenxian,Li Xingya...&Fang Wenfeng.(2022).Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.LUNG CANCER,172,
MLA：
Huang Yihua,et al."Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients".LUNG CANCER 172.(2022):117-123

相关文献

[1]医院后勤精细化管理策略研究 [2]个性化目标教学在神经外科护理实习生带教中的应用 [3]纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较 [4]徒手淋巴引流对乳腺癌术后淋巴水肿的治疗效果分析 [5]护理干预在减轻妇科恶性肿瘤腹部术后疼痛中的效果 [6]心理护理对肿瘤介入治疗患者生活质量的影响 [7]某院2400张门诊中成药处方分析 [8]人文关怀在恶性肿瘤护理中的应用效果分析 [9]综合护理干预对肺癌化疗患者生活质量的影响 [10]外涂万花油对化疗性静脉炎的预防及疗效

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号